Natriuretic peptide receptors, NPR-A and NPR-B, in cultured rabbit retinal pigment epithelium cells.
We tried to detect natriuretic peptide (NP) receptor (NPR-A and NPR-B) mRNAs in cultured rabbit retinal pigment epithelium (RPE) cells and examined the regulation of their expression in relation to subretinal fluid absorption or RPE cell proliferation. RPE cells from 2-4 passages were grown to confluence on microporous membranes and analyzed for levels of expression of receptor mRNAs by quantitative RT-PCR and Northern blotting. The expression of NPR-B mRNA was approximately tenfold higher than that of NPR-A mRNA. The expression of NPR-A mRNA was not affected by treatments that may change subretinal fluid transport, while that of NPR-B mRNA was inhibited by transmitters involved in light- and dark-adaptation such as dopamine and melatonin. Expression of NPR-B mRNA was also suppressed by platelet-derived growth factor and transforming growth factor-beta. Furthermore, atrial natriuretic peptide (ANP) and C-type natriuretic peptide (CNP), ligands for NPR-A and B, respectively, inhibited the proliferation of RPE cells, as analyzed by incorporation of [3H]thymidine. These findings suggest that ANP may be involved in constitutive absorption of subretinal fluid and that NPs form an important regulatory system of proliferation in RPE cells.
Fujiseki
Y
Y
Department of Pharmacology, Kansai Medical University, Moriguchi, Osaka, Japan.
Omori
K
K
Omori
K
K
Mikami
Y
Y
Suzukawa
J
J
Okugawa
G
G
Uyama
M
M
Inagaki
C
C
D000086:Acetazolamide / Q000494:pharmacology; D000818:Animals; D009320:Atrial Natriuretic Factor / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004298:Dopamine / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D006133:Growth Substances / Q000494:pharmacology; D006162:Guanylate Cyclase / Q000235:genetics*; D008353:Mannitol / Q000494:pharmacology; D008550:Melatonin / Q000494:pharmacology; D020098:Natriuretic Peptide, C-Type / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010857:Pigment Epithelium of Eye / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D012333:RNA, Messenger / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D011817:Rabbits; D017461:Receptors, Atrial Natriuretic Factor / Q000235:genetics*; D016212:Transforming Growth Factor beta / Q000494:pharmacology; D000099242:Atrial Natriuretic Factor Receptor B
D000086:Acetazolamide; D009320:Atrial Natriuretic Factor; D004298:Dopamine; D016222:Fibroblast Growth Factor 2; D006133:Growth Substances; D006162:Guanylate Cyclase; D008353:Mannitol; D008550:Melatonin; D020098:Natriuretic Peptide, C-Type; D009638:Norepinephrine; D010982:Platelet-Derived Growth Factor; D012333:RNA, Messenger; D017461:Receptors, Atrial Natriuretic Factor; D016212:Transforming Growth Factor beta; D000099242:Atrial Natriuretic Factor Receptor B; C091715:atrial natriuretic factor receptor A